| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.0094 | 0.9 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | GW-405833 | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | 0.0083 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.9 |